Your browser doesn't support javascript.
loading
FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.
Egbuna, Chukwuebuka; Patrick-Iwuanyanwu, Kingsley C; Onyeike, Eugene N; Khan, Johra; Alshehri, Bader.
Afiliação
  • Egbuna C; Africa Centre of Excellence in Public Health and Toxicological Research (ACE-PUTOR), University of Port-Harcourt, Port Harcourt, Rivers State, Nigeria.
  • Patrick-Iwuanyanwu KC; Department of Biochemistry, Faculty of Science, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.
  • Onyeike EN; Department of Biochemistry, Faculty of Natural Sciences, Chukwuemeka Odumegwu Ojukwu University, Uli, Anambra State, Nigeria.
  • Khan J; Africa Centre of Excellence in Public Health and Toxicological Research (ACE-PUTOR), University of Port-Harcourt, Port Harcourt, Rivers State, Nigeria.
  • Alshehri B; Department of Biochemistry, Faculty of Science, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.
J Biomol Struct Dyn ; 40(22): 12248-12259, 2022.
Article em En | MEDLINE | ID: mdl-34486940
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article